title: Current strategies to create tailored and risk-adapted therapies for CLL patients.
abstract: Given the current dynamics in the development of novel agents for CLL therapy, the task to find optimal, non-toxic combinations has become the primary goal. This article gives an update of the most interesting novel drugs. The strategy of the German CLL Study Group to use these agents in combinations is described in detail, highlighting the strategy and first results of a recently started series of phase II combination trials, the BXX series using agents such as bendamustine, idelalisib, ibrutinib, obinutuzumab, ofatumumab and venetoclax.
authors.affiliation: Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University Hospital, Cologne, Germany; German CLL Study Group, University Hospital Cologne, Cologne, Germany.
authors.forename: Paula
authors.initials: P
authors.lastname: Cramer
authors.affiliation: Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University Hospital, Cologne, Germany; German CLL Study Group, University Hospital Cologne, Cologne, Germany.
authors.forename: Barbara
authors.initials: B
authors.lastname: Eichhorst
authors.affiliation: Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University Hospital, Cologne, Germany; CECAD, University Hospital Cologne, Cologne Germany.
authors.forename: Hans Christian
authors.initials: HC
authors.lastname: Reinhardt
authors.affiliation: Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University Hospital, Cologne, Germany; German CLL Study Group, University Hospital Cologne, Cologne, Germany; CECAD, University Hospital Cologne, Cologne Germany. Electronic address: Michael.hallek@uni-koeln.de.
authors.forename: Michael
authors.initials: M
authors.lastname: Hallek
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D010880:Piperidines; D057285:Precision Medicine / Q000379:methods* / Q000592:standards; D011687:Purines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D052999:Quinazolinones / Q000627:therapeutic use; D012307:Risk Factors; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019086:Bridged Bicyclo Compounds, Heterocyclic; D010880:Piperidines; D011687:Purines; D011720:Pyrazoles; D011743:Pyrimidines; D052999:Quinazolinones; D013449:Sulfonamides; C551803:ibrutinib; D000069461:Bendamustine Hydrochloride; D000225:Adenine; C527517:ofatumumab; C579720:venetoclax; C543332:obinutuzumab; C552946:idelalisib
keywords: CLL; Ibrutinib; Idelalisib (CAL-101); MRD; Maintenance; Obinutuzumab (GA101); Ofatumumab; Venetoclax (ABT-199)